


## AMENDMENTS TO CLAIMS

This listing of claims will replace all prior versions and listings of claims in this application.

Claim 1 (Currently Amended): A compound of the general formula (I),



General Formula (I)

~~its derivative, its analog, its tautomeric form, its stereoisomer, its geometric form, its N-oxide, its polymorph, or its pharmaceutically acceptable salt, or its pharmaceutically acceptable solvate,~~  
 wherein

A ~~is~~ may be Carbon-only;

wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>14</sub> and R<sub>15</sub> may be same or different ~~and may be same or different~~ and each independently represent hydrogen, halogen, oxo, thio, perhaloalkyl, hydroxy, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (C<sub>1</sub>-C<sub>12</sub>)alkyl, (C<sub>2</sub>-C<sub>12</sub>)alkenyl, (C<sub>2</sub>-C<sub>12</sub>)alkynyl, (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)cycloalkenyl, bicycloalkyl, bicycloalkenyl, (C<sub>1</sub>-C<sub>12</sub>)alkoxy, cyclo(C<sub>3</sub>-C<sub>7</sub>)alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclylalkyloxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, alkoxycarbonyl, hydroxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxycarbonylamino, aralkyloxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkylamidino,

alkylguanidino, dialkylguanidino, carboxylic acid ~~and its derivatives~~, sulfonic acids ~~and its derivatives~~;

R<sub>16</sub> and R<sub>17</sub> may be the same or different and each independently represents Hydrogen, substituted or unsubstituted groups selected from linear or branched (C<sub>1</sub>–C<sub>12</sub>) (C<sub>1</sub> – C<sub>12</sub>) alkyl, (C<sub>2</sub>–C<sub>12</sub>) alkenyl, (C<sub>2</sub>–C<sub>12</sub>)alkynyl, (C<sub>3</sub>–C<sub>7</sub>)cycloalkyl, (C<sub>3</sub>–C<sub>7</sub>)cycloalkenyl, bicycloalkyl, bicycloalkenyl, aryl, aralkyl, heteroaryl or heterocyclalkyl;

R<sub>13</sub> along with either R<sub>16</sub> or R<sub>17</sub> and the two nitrogen atoms may form a piperazine or diazepine ring, which may be further substituted with R<sub>14</sub> and R<sub>15</sub>; and

n = 1.

Claim 2 (Currently Amended): A compound according to Claim ~~[[1]]~~1 which is selected from:

- 1-Benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole;
- 1-(4-Methylbenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole;
- 1-(4-Bromobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole;
- 1-(4-Fluorobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1H-indole;
- 1-(4-Methoxybenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole;
- 1-(4-Isopropylbenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole;
- 1-(2-Bromobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole;
- 1-(2-Bromobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole hydrochloride salt;
- 1-(2-Bromo-4-methoxybenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole;
- 4,5,6-Trichloro-1-benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole;
- 4,5,6-Trichloro-1- (4-methylbenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole;

1-(4-Bromobenzenesulfonyl)-4, 5, 6-trichloro-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole;

4,5, 6-Trichloro-1-(4-isopropylbenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;

1-(2-Bromobenzenesulfonyl)-4, 5, 6-trichloro-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole;

1-(2-Bromo-4-methoxybenzenesulfonyl)-4, 5, 6-trichloro-3-(4-methylpiperazin- ylmethyl)-1 H-indole;

1-Benzenesulfonyl-5-methoxy-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;

1-(4-Methylbenzenesulfonyl)-5-methoxy-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole;

1-(4-Bromobenzenesulfonyl)-5-methoxy-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole;

1-(4-Isopropylbenzenesulfonyl)-5-methoxy-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole;

1-(2-Bromobenzenesulfonyl)-5-methoxy-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole;

1-(2-Bromo-4-methoxybenzenesulfonyl)-5-methoxy-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;

1-(2-Bromo-4-methoxybenzenesulfonyl)-5-methoxy-3-(4-methylpiperazin-1-ylmethyl)- 1 H-indole hydrochloride salt;

1-(4-methoxybenzenesulfonyl)-5-methoxy-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole;

1-(4-Fluorobenzenesulfonyl)-5-methoxy-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole;

5-Bromo1-(4-fluorobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;

5-Bromo-1-(4-fluorobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole hydrochloride salt;

5-Bromo-1-(4-fluorobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole maleate salt;

5-Bromo-1-(4-fluorobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole citrate salt;

5-Bromo1-(4-methoxybenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;

5-Bromo-1-(benzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole;

5-Bromo-1-(4-methylbenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole;

5-Bromo1-(4-bromobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;

5-Bromo-1-(4-isopropylbenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;

5-Bromo-1-(2-bromobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;

5-Bromo-1-(2-bromobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole  
hydrochloride salt;

5-Bromo-1-(2-bromo-4-methoxybenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)- 1 H-indole;

4-Bromo-1-(4-fluorobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole;

4-Bromo-1-(4-methoxybenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole;

4-Bromo-1-(4-isopropylbenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;

(1-Benzenesulfonyl-1 H-indol-3-yl)-(4-methylpiperazin-1-yl) methanone;

[1-(4-Methylbenzenesulfonyl)-1 H-indol-3-yl]-(4-methylpiperazin-1-yl) methanone;

[1-(4-Isopropylbenzenesulfonyl)-1 H-indol-3-yl]-(4-methylpiperazin-1-yl) methanone;

[1-(2-Bromobenzenesulfonyl)-1 H-indol-3-yl]-(4-methylpiperazin-1-yl) methanone;

[1-(2-Bromo-4-methoxybenzenesulfonyl)-1 H-indol-3-yl]-(4-methylpiperazin-1-yl)  
methanone;

(1-Benzenesulfonyl)-5-nitro-1 H-indol-3-yl]-(4-methylpiperazin-1-yl) methanone;

[1-(4-Methylbenzenesulfonyl)-5-nitro-1 H-indol-3-yl]-(4-methylpiperazin-1-yl)  
methanone;

[1-(4-Fluorobenzenesulfonyl)-5-nitro-1 H-indol-3-yl]-(4-methylpiperazin-1-yl)  
methanone;

[1-(4-Bromobenzenesulfonyl)-5-nitro-1H-indol-3-yl]-(4-methylpiperazin-1-yl) methanone;

[1-(4-Isopropylbenzenesulfonyl)-5-nitro-1 H-indol-3-yl]-(4-methylpiperazin-1-yl)  
methanone;

[1-(2-Bromobenzenesulfonyl)-5-nitro-1 H-indol-3-yl]-(4-methylpiperazin-1-yl)  
methanone;

[1-(4-Methoxybenzenesulfonyl)-5-nitro-1 H-indol-3-yl]-(4-methylpiperazin-1-yl)  
methanone;

[1-(2-Bromo-4-methoxybenzenesulfonyl)-5-nitro-1 H-indol-3-yl]-(4-methylpiperazin-1-yl)  
methanone;

1-Benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole;

1-(4-Methylbenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole;

1-(4-Fluorobenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;

1-(4-Bromobenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole;

1-(4-Isopropylbenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole;

1-(2-Bromobenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole;

1-(2-Bromobenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole hydrochloride salt;

1-(2-Bromo-4-methoxybenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole;

1-(2-Bromo-4-methoxybenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1 H-indole hydrochloride salt;

1-(4-methoxybenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;

1-(2-Bromo-4-methoxybenzenesulfonyl)-5-chloro-2-methyl-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole;

5-Chloro-1-(4-fluorobenzenesulfonyl)-2-methyl-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole;

1-(4-Bromobenzenesulfonyl)-5-chloro-2-methyl-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole;

5-Chloro-1-(4-Isopropylbenzenesulfonyl)-2-methyl-3-(4-methylpiperazin-1-ylmethyl)- 1 H-indole;

1-Benzenesulfonyl-5-chloro-2-phenyl-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole;

5-Chloro-1-(4-methylbenzenesulfonyl)-2- phenyl-3- (4-methylpiperazin-1-ylmethyl)- 1 H-indole;

1-(Benzenesulfonyl)- 5-fluoro-2-phenyl-3- (4-methylpiperazin-1-yimethyl)-1 H-indole;

5-Fluoro-1-(4-methylbenzenesulfonyl)-2-phenyl-3- (4-methylpiperazin-1-ylmethyl)-1H-indole;

1-(4-Bromobenzenesulfonyl)-5-chloro-2-phenyl-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;

1- (2-Bromobenzenesulfonyl)-5-cyano-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole;

5-Cyano-1-(4-methoxybenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole;

5-Cyano-1-(4-fluorobenzenesulfonyl)-3- (4-methyl piperazin-1-ylmethyl)-1 H-indole;

1-(4-Bromobenzenesulfonyl)-5-cyano-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;

5-Cyano-1-(4-Isopropylbenzenesulfonyl)-3-(4-methylpiperazin-1-ylmethyl)-1H-indole;

N-(1-(4-Fluorobenzenesulfonyl)-1H-indol-3-yl)methyl-N, N', N'-trimethylethylene-1, 2-diamine;

N-(1-(4-Fluorobenzenesulfonyl)-1H-indol-3-yl)methyl-N, N', N'-trimethylethylene-1, 2-diamine hydrochloride salt;

N-(1-(4-Bromobenzenesulfonyl)-5-bromo-1H-indol-3-yl)methyl-N, N', N'-trimethylethylene-1, 2-diamine;

N-(1-(4-Bromobenzenesulfonyl)-5-bromo-1H-indol-3-yl)methyl-N, N', N'-trimethylethylene-1, 2-diamine hydrochloride salt;

N-(5-Bromo-1-(4-methoxybenzenesulfonyl)-1H-indol-3-yl)methyl-N, N', N'-trimethylethylene-1, 2-diamine;

N-(1-(4-Methoxybenzenesulfonyl)-5-nitro-1H-indol-3-yl)methyl-N, N', N'-trimethylethylene-1, 2-diamine;

N-(1-(4-Methoxybenzenesulfonyl)-5-nitro-1H-indol-3-yl)methyl-N, N', N'-trimethylethylene-1, 2-diamine hydrochloride salt;

N-(1-(2-Bromobenzenesulfonyl)-5-bromo-1H-indol-3-yl)methyl-N, N', N'-trimethylethylene-1, 2-diamine;

1-(2-Bromobenzenesulfonyl)-3-(4-(3-chlorobenzene-1-yl)piperazin-1-ylmethyl)-1H-indole;

1-(4-Methoxybenzenesulfonyl)-3-(4-(2-methoxybenzene-1-yl)piperazin-1-ylmethyl)-1H-indole;

1-(2-Bromo-4-methoxybenzenesulfonyl)-3-(4-(2-methoxybenzene-1-yl)piperazin-1-ylmethyl)-1H-indole;

1-(4-Isopropylbenzenesulfonyl)-3-(4-(2-methoxybenzene-1-yl)piperazin-1-ylmethyl)-1H-indole;

5-Bromo-1-(4-fluorobenzenesulfonyl)-3-(4-(2-methoxybenzene-1-yl)piperazin-1-ylmethyl)-1H-indole;

5-Bromo-1-(4-methoxybenzenesulfonyl)-3-(4-(2-methoxybenzene-1-yl)piperazin-1-ylmethyl)-1H-indole;

5-Bromo-1-(4-isopropylbenzenesulfonyl)-3-(4-(2-methoxybenzene-1-yl)piperazin-1-ylmethyl)-1H-indole;

1-(4-Fluorobenzenesulfonyl)-5-methoxy-3-(4-(2-methoxybenzene-1-yl)piperazin-1-ylmethyl)-1H-indole;

1-(4-Fluorobenzenesulfonyl)-5-methoxy-3-(4-(2-methoxybenzene-1-yl) piperazin-1-ylmethyl)-1 H-indole hydrochloride salt;

1-(4-Methoxybenzenesulfonyl)-5-methoxy-3-(4-(2-methoxybenzene-1-yl) piperazin-1-ylmethyl)-1 H-indole;

1-(4-Isopropylbenzenesulfonyl)-5-methoxy-3-(4-(2-methoxybenzene-1-yl) piperazin-1-ylmethyl)-1H-indole;

1-(4-Fluorobenzenesulfonyl)-3-(4-pyridin-2-yl)piperazin-1-ylmethyl)-1H-indole;

1-(4-Methoxybenzenesulfonyl)-3-(4-(pyridin-2-yl) piperazin-1-ylmethyl)-1 H-indole;

1-(4-Isopropylbenzenesulfonyl)-3-(4-(pyridin-2-yl)piperazin-1-ylmethyl)-1H-indole ;

1-(2-Bromobenzenesulfonyl)-3-(4-(pyridin-2-yl) piperazin-1-ylmethyl)-1 H-indole;

1-(2-Bromo-4-methoxybenzenesulfonyl)-3-(4-(pyridin-2-yl) piperazin-1-ylmethyl)-1 H-indole;

5-Bromo-1-(4-fluorobenzenesulfonyl)-3-(4-(pyridin-2-yl) piperazin-1-ylmethyl)-1 H-indole;

5-Bromo-1-(4-methoxybenzenesulfonyl)-3-(4-(pyridin-2-yl) piperazin-1-ylmethyl)-1 H-indole;

5-Bromo-1-(4-isopropylbenzenesulfonyl)-3-(4-(pyridin-2-yl) piperazin-1-ylmethyl)-1 H-indole;

1-(4-Fluorobenzenesulfonyl)-5-methoxy-3-(4-(pyridin-2-yl) piperazin-1-ylmethyl)-1 H-indole;

1-(4-Methoxybenzenesulfonyl)-5-methoxy-3-(4-(pyridin-2-yl) piperazin-1-ylmethyl)-1 H-indole;

1-(4-Isopropylbenzenesulfonyl)-5-methoxy-3-(4-(pyridin-2-yl) piperazin-1-ylmethyl)- 1 H-indole;

1-(4-Isopropylbenzenesulfonyl)-5-methoxy-3-(4-(benzyl) piperazin-1-ylmethyl)-1 H-indole;

1-(4-Methoxybenzenesulfonyl)-5-methoxy-3-(4-(benzyl) piperazin-1-ylmethyl)-1 H-indole;

1-(4-Isopropylbenzenesulfonyl)-3-(4-(benzyl) piperazin-1-ylmethyl)-1 H-indole;

1-(4-Methoxybenzenesulfonyl)-3-(4-(benzyl) piperazin-1-ylmethyl)-1 H-indole;

1-(2-Bromo-4-methoxybenzenesulfonyl)- 3-(4-(benzyl) piperazin-1-ylmethyl)-1 H-indole;

1-(Benzenesulfonyl)-3-(4-(benzyl)piperazin-1-ylmethyl)-1H-indole;

1-(4-Methoxybenzenesulfonyl)-3-2- [1, 4] Diazepan-1-ylmethyl-1 H-indole;

(R, S) 1- (1-Benzenesulfonyl-indol-3-yl)-1- (4-methylpiperazin-1-yl) ethane;

(R) 1- (1-Benzenesulfonyl-indol-3-yl)-1- (4-methylpiperazin-1-yl) ethane;

(S) 1- (1-Benzenesulfonyl-indol-3-yl)-1- (4-methylpiperazin-1-yl) ethane;

(R, S) 1- [1- (4-Methylbenzenesulfonyl) indol-3-yl]-1- (4-methylpiperazin-1-yl) ethane;

(R) 1- [1- (4-Methylbenzenesulfonyl) indol-3-yl]-1- (4-methylpiperazin-1-yl) ethane;

(S) 1- [1- (4-Methylbenzenesulfonyl) indol-3-yl]-1- (4-methylpiperazin-1-yl) ethane;

(R, S) 1-[1-(4-Methoxybenzenesulfonyl) indol-3-yl]-1-(4-methylpiperazin-1-yl) ethane;

(R) 1-[1-(4-Methoxybenzenesulfonyl) indol-3-yl]-1-(4-methylpiperazin-1-yl) ethane;

(S) 1- [1- (4-Methoxybenzenesulfonyl) indol-3-yl]-1- (4-methylpiperazin-1-yl) ethane;

(R, S) 1- [1- (4-Isopropylbenzenesulfonyl) indol-3-yl]-1- (4-methylpiperazin-1-yl) ethane;

(R) 1-[1-(4-Isopropylbenzenesulfonyl) indol-3-yl]-1-(4-methylpiperazin-1-yl) ethane;

(S) 1- [1- (4-Isopropylbenzenesulfonyl) indol-3-yl]-1- (4-methylpiperazin-1-yl) ethane;

1-(4-Fluorobenzenesulfonyl)-1H-indole-3-carboxylic acid N-(N, N- dimethylaminoethyl)-N-methylamide;

1-(4-Methoxybenzenesulfonyl)-1H-indole-3-carboxylic acid N- (N, N- dimethylaminoethyl)-N-methylamide;

1-(4-Isopropylbenzenesulfonyl)-1 H-indole-3-carboxylic acid N- (N', N'- dimethylaminoethyl)-N-methylamide;

(R, S)  $\alpha$ - [1- (4-Methoxybenzenesulfonyl)-1 H-indol-3-yl]- $\alpha$ - (4-methylpiperazin-1- yl) acetonitrile;

(R)  $\alpha$ - [1- (4-Methoxybenzenesulfonyl)-1H-indol-3-yl]- $\alpha$ - (4-methylpiperazin-1- y,) acetonitrile;

(S)  $\alpha$ - [1- (4-Methoxybenzenesulfonyl)-1 H-indol-3-yl]- $\alpha$ - (4-methylpiperazin-1- yl) acetonitrile;

(R, S)  $\alpha$ -[1- (Benzenesulfonyl)-1 H-indol-3-yl]- $\alpha$ - (4-methylpiperazin-1-yl) acetonitrile;

(R)  $\alpha$ - [1- (Benzenesulfonyl)-1 H-indol-3-yl]- $\alpha$ - (4-methylpiperazin-1-yl) acetonitrile ;

(S)  $\alpha$ - [1- (Benzenesulfonyl)-1 H-indol-3-yl]- $\alpha$ - (4-methylpiperazin-1-yl) acetonitrile;

(R, S)  $\alpha$ - [1- (4-Isopropylbenzenesulfonyl)-1H-indol-3-yl]- $\alpha$ - (4-methylpiperazin-1-yl)- acetonitrile;



(R)  $\alpha$ -[1-(4-Isopropylbenzenesulfonyl)-1H-indol-3-yl]- $\alpha$ -(4-methylpiperazin-1-yl)-acetonitrile;

(S)  $\alpha$ -[1-(4-Isopropylbenzenesulfonyl)-1H-indol-3-yl]- $\alpha$ -(4-methylpiperazin-1-yl)-acetonitrile;

1-(Benzenesulfonyl)-3-(4-(benzyloxycarbonyl)-piperazin-1-yl methyl)-1H-indole;

1-(Benzenesulfonyl)-3-(4H-piperazin-1-ylmethyl)-1H-indole;

1-(4-Methoxybenzenesulfonyl)-3-(4H-piperazin-1-ylmethyl)-1H-indole

1-(4-Isopropylbenzenesulfonyl)-3-(4H-piperazin-1-ylmethyl)-1H-indole

1-(2-Bromo-4-methoxybenzenesulfonyl)-3-(4H-piperazin-1-ylmethyl)-1H-indole

5-Bromo-1-(benzenesulfonyl)-3-(4H-piperazin-1-ylmethyl)-1H-indole;

5-Bromo-1-(4-methoxybenzenesulfonyl)-3-(4H-piperazin-1-ylmethyl)-1H-indole

5-Bromo-1-(4-isopropylbenzenesulfonyl)-3-(4H-piperazin-1-ylmethyl)-1H-indole

5-Bromo-1-(2-bromo-4-methoxybenzenesulfonyl)-3-(4H-piperazin-1-ylmethyl)-1H-indole

1-[[1-(4-Isopropylbenzenesulfonyl)-indol-3-yl]methyl] [1, 4] diazepane

1-[[1-(2-Bromo-4-methoxybenzenesulfonyl)-indol-3-yl]methyl] [1,4] diazepane

1-[(1-(4-methylbenzenesulfonyl)-indol-3-yl) methyl] [1,4] diazepane

1-[[5-Bromo-1-(4-Methoxybenzenesulfonyl)-indol-3-yl]methyl][1, 4] diazepane

1-[[5-Bromo-1-(4-Isopropylbenzenesulfonyl)-indol-3-yl]methyl][1, 4] diazepane

1-[[5-Bromo-1-(2-Bromo-4-methoxybenzenesulfonyl)-indol-3-yl]methyl][1, 4] diazepane

1-[(5-Bromo-1-(4-methylbenzenesulfonyl)-indol-3-yl) methyl] [1,4] diazepane and their pharmaceutically acceptable salts[.], and polymorphs and solvates.

Claim 3 (Currently Amended): A pharmaceutical composition comprising either of a pharmaceutically acceptable carrier, a diluent, or excipients or ~~solvate~~ along with a therapeutically effective amount of a compound according to claim[1], ~~its derivative, its analogs,~~ its tautomeric forms, its stereoisomers, its geometric forms, ~~its N-oxides,~~ its

polymorphs, or its pharmaceutically acceptable salts, ~~or its pharmaceutically acceptable~~  
solvates.

Claim 4 (Original): A pharmaceutical composition according to claim-3, in the form of a tablet, capsule, powder, syrup, injectable solution or suspension.

Claims 5-14. Cancelled.

Claim 15 (Currently Amended): A method for the treatment and/or prophylaxis of clinical conditions such as anxiety, convulsive disorders, obsessive-compulsive disorders, migraine headache, cognitive memory disorders, ADHD (Attention Deficient Disorder/Hyperactivity Syndrome), personality disorders, psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schizophreniform disorders, withdrawal from drug abuse, panic attacks, sleep disorders and also disorders associated with spinal trauma and/or head injury which comprises the step of administering to a patient in need thereof, an effective amount of a compound of general formula (I) as claimed in claim 1.

Claims 16-19. Cancelled.

Claim 20 (Currently Amended): A process for the preparation of a compound of general formula (I) in accordance with Claim 1 wherein A is Carbon ~~may be CH<sub>2</sub>, C=O or SO<sub>2</sub>;~~  
~~R<sub>11</sub> and R<sub>12</sub> refer to substitutions on the carbon whenever A is CH<sub>2</sub>;~~

wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>14</sub> and R<sub>15</sub> may be the same or different ~~and may be same or different~~ and each independently represent hydrogen, halogen, oxo, thio, perhaloalkyl, hydroxy, amino, nitro, cyano, formyl, amidino, guanidino, substituted or


unsubstituted groups selected from linear or branched (C<sub>1</sub>-C<sub>12</sub>)alkyl, (C<sub>2</sub>-C<sub>12</sub>)alkenyl, (C<sub>2</sub>-C<sub>12</sub>)alkynyl, (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)cycloalkenyl, bicycloalkyl, bicycloalkenyl, (C<sub>1</sub>-C<sub>12</sub>)alkoxy, cyclo(C<sub>3</sub>-C<sub>7</sub>)alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclalkyloxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, alkoxycarbonyl, hydroxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxy carbonylamino, aralkyloxy carbonylamino, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkylamidino, alkylguanidino, dialkylguanidino, carboxylic acid and its derivatives, sulfonic acids and its derivatives;

R<sub>16</sub> and R<sub>17</sub> may be the same or different and each independently represents Hydrogen, substituted or unsubstituted groups selected from linear or branched (C<sub>1</sub>-C<sub>12</sub>)alkyl, (C<sub>2</sub>-C<sub>12</sub>)alkenyl, (C<sub>2</sub>-C<sub>12</sub>)alkynyl, (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)cycloalkenyl, bicycloalkyl, bicycloalkenyl, aryl, aralkyl, heteroaryl or heterocyclalkyl;


R<sub>13</sub> along with either R<sub>16</sub> or R<sub>17</sub> and the two nitrogen atoms may form a piperazine or diazepine ring, which may be further substituted with R<sub>14</sub> and R<sub>15</sub>; and

n = 1;

which comprises reacting a compound of formula (IV) given below,



wherein all the symbols are as defined earlier with a compound of formula (V),



(V)


where all the symbols are as defined earlier; and X is halogen, preferably chloro, bromo or iodo.

Claims 21-25 Cancelled.

Claim 26 (Currently Amended): A process according to Claim 20 comprising of carrying out one or more of the following optional steps: i) removing any protecting group; ii) resolving the racemic mixture into pure enantiomers by the known methods and iii) preparing a pharmaceutically acceptable salt of a compound of formula (I) and/or (iv) preparing a pharmaceutically acceptable prodrug thereof.

Claims 27-30 Cancelled.

Claim 31 (Original): Novel compounds of general formula (IV) is defined below,



(IV)

wherein all symbols are as defined earlier.

Claim 32      Cancelled.

Claim 33.      (New): A method for the treatment and/or prophylaxis of a cognitive disorder comprising the step of administering to a patient in need thereof, an effective amount of a compound of general formula (I) as claimed in claim 1.

Claim 34.      (New): The method of claim 15, wherein said condition is Alzheimer's disease.

Claim 35.      (New): The method of claim 15, wherein said condition is schizophrenia.